- Viral Glycobiology
- Therapeutic Antibodies
Viral Glycobiology: Our work assisting the development of an HIV vaccine is based on targeting the carbohydrate coat of HIV that shields the virus. We have shown that this shield is different from normal “self” carbohydrates and is remarkably constant despite huge variation in the underlying protein. We also study glycoproteins from a large range of other viruses including influenza and coronaviruses such as SARS-CoV-2.
Therapeutic Antibodies: Antibodies are incredibly versatile therapeutics and can exhibit both pro- and anti-inflammatory properties. For this reason, they are being applied to the treatment of conditions ranging from cancers to autoimmune disorders. Anti-cancer antibodies often rely on the recruitment of the immune system to cancerous cells through a constant region of the antibody termed the Fc region. We have structurally characterized how different glycans can impact on Fc structure and how they can be manipulated to fine-tune antibody effector functions. In addition, we are developing bispecific antibodies and a new approach for enhancing therapeutic antibodies against cancer that involves deactivating competing endogenous antibodies that can limit the potency of anti-cancer antibodies. We are very proud to be sponsored by Against Breast Cancer.
Current PhD Students
External roles and responsibilities
Professor Max Crispin runs the Glycoprotein Therapeutics Laboratory which is predominantly focussed on developing anti-viral vaccines and new antibody-based therapies against cancer.
In the Glycoprotein Therapeutics Laboratory we exploit the glycan modifications of proteins in the design of vaccines candidates and glycoprotein-based therapeutics. We have a particular interest in vaccine design against the Human Immunodeficiency Virus (HIV) and in the development of novel antibody-based cancer therapeutics. This involves understanding how glycans impact on protein and viral function, how they are structured, and how we they can be manipulated for therapeutic applications.
- Supernumerary Fellowship at Oriel College, Oxford (2018)
- FRSB (2016)
- FRSC (2020)
- Highly Cited Researcher 2019 (2019)